Goldman Sachs Group Inc Ultragenyx Pharmaceutical Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 506,510 shares of RARE stock, worth $22.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
506,510
Previous 629,514 19.54%
Holding current value
$22.7 Million
Previous $25.9 Million 8.75%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$40.21 - $59.36 $4.95 Million - $7.3 Million
-123,004 Reduced 19.54%
506,510 $28.1 Million
Q2 2024

Aug 13, 2024
BUY
$37.42 - $51.61 $9.93 Million - $13.7 Million
265,392 Added 72.89%
629,514 $25.9 Million
Q1 2024

May 15, 2024
BUY
$43.02 - $53.69 $8.99 Million - $11.2 Million
209,070 Added 134.84%
364,122 $17 Million
Q4 2023

Feb 13, 2024
SELL
$31.73 - $49.19 $7.5 Million - $11.6 Million
-236,251 Reduced 60.38%
155,052 $7.41 Million
Q3 2023

May 14, 2024
BUY
$34.92 - $46.66 $8.25 Million - $11 Million
236,251 Added 152.37%
391,303 $13.9 Million
Q3 2023

Nov 14, 2023
SELL
$34.92 - $46.66 $5.08 Million - $6.79 Million
-145,425 Reduced 27.09%
391,303 $13.9 Million
Q2 2023

May 14, 2024
BUY
$37.35 - $52.15 $3.43 Million - $4.78 Million
91,721 Added 20.61%
536,728 $24.8 Million
Q2 2023

Aug 14, 2023
BUY
$37.35 - $52.15 $3.43 Million - $4.78 Million
91,721 Added 20.61%
536,728 $24.8 Million
Q1 2023

May 14, 2024
SELL
$36.99 - $48.71 $24.8 Million - $32.6 Million
-669,311 Reduced 60.06%
445,007 $17.8 Million
Q1 2023

May 11, 2023
SELL
$36.99 - $48.71 $24.8 Million - $32.6 Million
-669,311 Reduced 60.06%
445,007 $17.8 Million
Q4 2022

May 14, 2024
BUY
$33.72 - $46.33 $3.48 Million - $4.78 Million
103,130 Added 10.2%
1,114,318 $51.6 Million
Q4 2022

Feb 13, 2023
BUY
$33.72 - $46.33 $3.48 Million - $4.78 Million
103,130 Added 10.2%
1,114,318 $51.6 Million
Q3 2022

May 14, 2024
BUY
$39.96 - $66.14 $6.04 Million - $9.99 Million
151,113 Added 17.57%
1,011,188 $41.9 Million
Q3 2022

Nov 10, 2022
BUY
$39.96 - $66.14 $6.04 Million - $9.99 Million
151,113 Added 17.57%
1,011,188 $41.9 Million
Q2 2022

May 14, 2024
BUY
$45.8 - $85.4 $32.3 Million - $60.2 Million
705,023 Added 454.7%
860,075 $51.3 Million
Q2 2022

Aug 15, 2022
BUY
$45.8 - $85.4 $4.25 Million - $7.93 Million
92,834 Added 12.1%
860,075 $51.3 Million
Q1 2022

May 16, 2022
BUY
$62.2 - $84.4 $2.59 Million - $3.51 Million
41,563 Added 5.73%
767,241 $55.7 Million
Q4 2021

Feb 14, 2022
BUY
$73.71 - $87.86 $16.2 Million - $19.3 Million
219,470 Added 43.36%
725,678 $61 Million
Q3 2021

Nov 10, 2021
BUY
$77.92 - $102.4 $39.4 Million - $51.8 Million
506,208 New
506,208 $45.7 Million

Others Institutions Holding RARE

# of Institutions
325
Shares Held
85.7M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.13B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email